MARKET

GOSS

GOSS

Gossamer Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.00
+0.14
+1.58%
Opening 12:10 11/25 EST
OPEN
8.92
PREV CLOSE
8.86
HIGH
9.00
LOW
8.81
VOLUME
125.51K
TURNOVER
--
52 WEEK HIGH
27.15
52 WEEK LOW
7.52
MARKET CAP
683.35M
P/E (TTM)
-2.5214
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that the Company’s Board of Directors has appointed Faheem Hasnain as Chief Executive Officer and President, effective immediately. Mr. Hasnain is a Co-Founder, former Chief Executive Officer, and current Chairman of Gossamer Bio. Mr. Hasnain succeeds Sheila Gujrathi, M.D., a Co-Founder of Gossamer Bio, who served as Chief Executive Officer and President since July 2018. Dr. Gujrathi will continue in an advisory role to the Company.
Business Wire · 11/16 12:01
Gossamer Bio EPS beats by $0.04
Gossamer Bio (GOSS): Q3 GAAP EPS of -$0.80 beats by $0.04.Cash, equivalents and marketable securities totaled $555M.Shares -0.65%.Press Release
Seekingalpha · 11/10 21:29
Gossamer Bio, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 10, 2020 / Gossamer Bio, Inc.
ACCESSWIRE · 11/10 19:30
Gossamer Bio Announces GB1275 Data Presentations At Upcoming 2020 Society For Immunotherapy Of Cancer Annual Meeting Nov. 9-14
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and
Benzinga · 11/06 12:12
Insider Weekends: Director Of Selecta Biosciences Purchases Over Half A Million Dollars' Worth Of Stock
Insider buying decreased once again last week.Notable Insider Buys: Gossamer Bio, Inc., Selecta Biosciences, Inc., Citigroup Inc., Loop Industries, Inc., and BioVie Inc.Notable Insider Sells: Okta, Inc., Paycom Software, Inc., Apple Inc., salesforce.com, inc., and Workday, Inc.
Seekingalpha · 10/19 10:04
Mid-Afternoon Market Update: Dow Falls 200 Points; Gossamer Bio Shares Plummet
Toward the end of trading Tuesday, the Dow traded down 0.71% to 28,630.33 while the NASDAQ fell 0.20% to 11852.15. The S&P also fell, falling 0.78% to 3,506.79.
Benzinga · 10/13 18:38
SOL, MGI, WWR and ICON among midday movers
Gainers: Medigus (MDGS) +74%.PEDEVCO (PED) +46%.Larimar Therapeutics (LRMR) +23%.Oblong (OBLG) +23%.Blonder Tongue Laboratories (BDR) +21%.BiondVax Pharmaceuticals (BVXV) +19%.Enlivex Therapeutics (ENLV) +19%.Aileron Therapeutics (ALRN) +17%.MoneyGram International (MGI) +15%.ReneSola (SOL) +15%.Losers: Gossamer Bio (GOSS) -34%.Loop Industries
Seekingalpha · 10/13 16:38
Mid-Day Market Update: Gold Down 2%; Medigus Shares Spike Higher
Midway through trading Tuesday, the Dow traded down 0.25% to 28,766.88 while the NASDAQ rose 0.19% to 11,899.41. The S&P also fell, falling 0.28% to 3,524.36.
Benzinga · 10/13 16:18
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GOSS. Analyze the recent business situations of Gossamer Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GOSS stock price target is 20.00 with a high estimate of 29.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 164
Institutional Holdings: 61.72M
% Owned: 81.28%
Shares Outstanding: 75.93M
TypeInstitutionsShares
Increased
50
4.33M
New
30
915.67K
Decreased
29
2.20M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.54%
Pharmaceuticals & Medical Research
+0.33%
Key Executives
Chairman/President/Chief Executive Officer/Director
Faheem Hasnain
Non-Executive Chairman
faheem Hasnain
Chief Financial Officer
Bryan Giraudo
Executive Vice President/General Counsel
Christian Waage
Other
Jakob Dupont
Director
Russell J. Cox
Other
Luisa Salter-Cid
Independent Director
Joshua Bilenker
Independent Director
Kristina Burow
Independent Director
Russell Cox
Independent Director
Thomas Daniel
Independent Director
Renee Gala
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GOSS
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company has six programs: three clinical-stage product candidates and three preclinical programs. Its pipeline includes GB001, GB002, GB004, GB1275, Autoimmune program and Oncology program. GB001 is an oral antagonist of prostaglandin D2 receptor 2, or DP2, is being developed for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. GB002 is an orally inhaled, small molecule, selective platelet-derived growth factor, or PDGF, receptor kinase inhibitor is being developed for the treatment of pulmonary arterial hypertension. GB004 is being developed for Inflammatory Bowel Disease (IBD). GB1275 is a CD11b agonist.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Gossamer Bio Inc stock information, including NASDAQ:GOSS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GOSS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GOSS stock methods without spending real money on the virtual paper trading platform.